secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001193125-26-170572
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics appoints June Bray as independent director, expands board to four members
--------------------------------------------------------------------------------

- June Bray appointed as Class I director effective April 22, 2026, filling a vacancy on the four-member board.
- Bray is deemed independent and will serve on Nominating & Governance, Audit, and Compensation Committees.
- Director compensation: $38,000 annual board retainer plus $7,500 (Nominating & Gov), $5,500 (Audit), $4,000 (Comp); no initial option grant.
- Bray will enter the company's standard form of indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526170572/0001193125-26-170572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526170572/d27180d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-170572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer